The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 04, 2019

Filed:

Jan. 13, 2017
Applicant:

Light Sciences Oncology, Inc., Bellevue, King County, WA (US);

Inventors:

Llew Keltner, Portland, OR (US);

Jay Winship, Bellevue, WA (US);

Erik Hagstrom, Woodinville, WA (US);

Frank Zheng, Kirkland, WA (US);

James C. Chen, Clyde Hill, WA (US);

Joseph M. Hobbs, Issaquah, WA (US);

Assignee:

LIGHT SCIENCES ONCOLOGY INC., Bellevue, King County, WA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61N 5/06 (2006.01); A61K 41/00 (2006.01); A61B 17/00 (2006.01); A61B 17/22 (2006.01); A61B 18/00 (2006.01); A61B 18/22 (2006.01); A61N 5/067 (2006.01);
U.S. Cl.
CPC ...
A61N 5/062 (2013.01); A61K 41/0071 (2013.01); A61N 5/0601 (2013.01); A61N 5/0603 (2013.01); A61B 2017/00084 (2013.01); A61B 2017/00274 (2013.01); A61B 2017/22068 (2013.01); A61B 2018/00285 (2013.01); A61B 2018/00547 (2013.01); A61B 2018/00821 (2013.01); A61B 2018/2261 (2013.01); A61N 2005/061 (2013.01); A61N 2005/0602 (2013.01); A61N 2005/063 (2013.01); A61N 2005/067 (2013.01); A61N 2005/0652 (2013.01);
Abstract

A prostate treatment system having a light delivery device positionable in a transurethral device for treatment of benign prostatic hyperplasia (BPH). The light delivery device includes light generator, such as light emitting diodes (LED), laser diodes (LDs) or a diffusion quartz fiber tip connected to a light generator or a light emitting polymer which produces light at a selected wavelength or waveband or alternative sources of suitable light energy. The treatment device may further include a temperature monitoring system for monitoring the temperature at the treatment site. A light-activated drug is administered to the treatment site prior to light activation. The light-activated drug therapy induces cell death of the target tissue. The device provides a minimally invasive transurethral method for treatment of BPH or prostate cancer.


Find Patent Forward Citations

Loading…